Tardive Dyskinesia | A Drug Pipeline Analysis Report 2018 | Technavio
LONDON--(BUSINESS WIRE)--Aug 6, 2018--Technavio has announced their latest analysis report on drug pipeline for . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat tardive dyskinesia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180806005264/en/
Technavio has published a new report on the drug development pipeline for tardive dyskinesia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Tardive dyskinesia: Market overview
Tardive dyskinesia is a socially stigmatizing long-term side effect, which may occur with certain antipsychotic medications that are generally prescribed for conditions such as schizophrenia and schizoaffective disorder.
According to a senior market research analyst at Technavio, “Tardive dyskinesia syndrome is characterized by repetitive, involuntary, and jerking movements in the face, neck, and tongue. The symptoms of tardive dyskinesia can be very troubling for patients and family members. The muscle movements of the patient, especially in the face, neck, and tongue get out of control.”
Tardive dyskinesia: Segmentation analysis
This pipeline analysis report segments the tardive dyskinesia market based on therapies employed (monotherapy), RoA (oral), therapeutic modality (small molecule), targets (VMAT2, dopamine receptor, and purinergic P2 receptor), MoA (VMAT2 inhibitor, dopamine receptor agonist, and purinergic P2 receptor antagonist), geographical segmentation (Czech Republic, Germany, Hungary, Japan, Poland, Slovakia, and the US) and recruitment status (active, not recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on the mechanism of action, around 50% of the molecules that are being investigated for the treatment of tardive dyskinesia are VMAT2 inhibitors.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180806005264/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL OTHER HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 08/06/2018 03:49 AM/DISC: 08/06/2018 03:49 AM